OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results
Abdulraheem Yacoub, Uma Borate, Raajit K. Rampal, et al.
Blood Advances (2024) Vol. 8, Iss. 6, pp. 1515-1528
Open Access | Times Cited: 8
Abdulraheem Yacoub, Uma Borate, Raajit K. Rampal, et al.
Blood Advances (2024) Vol. 8, Iss. 6, pp. 1515-1528
Open Access | Times Cited: 8
Showing 8 citing articles:
Targeting PI3K in Cancer Treatment: A Comprehensive Review with Insights from Clinical Outcomes
Munier Hossain, Md. Arafat Hossain
European Journal of Pharmacology (2025), pp. 177432-177432
Closed Access
Munier Hossain, Md. Arafat Hossain
European Journal of Pharmacology (2025), pp. 177432-177432
Closed Access
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
Giuseppe Gaetano Loscocco, Paola Guglielmelli
American Journal of Hematology (2025)
Open Access
Giuseppe Gaetano Loscocco, Paola Guglielmelli
American Journal of Hematology (2025)
Open Access
SOHO State of the Art Updates and Next Questions: Novel Therapeutic Strategies in Development for Myelofibrosis
Helen T. Chifotides, Lucia Masarová, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 4, pp. 219-231
Open Access | Times Cited: 6
Helen T. Chifotides, Lucia Masarová, Srđan Verstovšek
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 4, pp. 219-231
Open Access | Times Cited: 6
Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B‐cell malignancies: Results from the CITADEL ‐101 study
Jia Li, Xiaohua Gong, Xing Liu, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 1
Jia Li, Xiaohua Gong, Xing Liu, et al.
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 2
Open Access | Times Cited: 1
Identifying disease-modifying potential in myelofibrosis clinical trials
David M. Ross, Steven Lane, Claire Harrison
Blood (2024) Vol. 144, Iss. 16, pp. 1679-1688
Closed Access | Times Cited: 1
David M. Ross, Steven Lane, Claire Harrison
Blood (2024) Vol. 144, Iss. 16, pp. 1679-1688
Closed Access | Times Cited: 1
Janus kinase inhibitor monotherapy and combination therapies for myelofibrosis: what’s the current standard of care?
Mahesh Swaminathan, Akhil Jain, Sungchul Daniel Choi, et al.
Expert Review of Hematology (2024)
Closed Access | Times Cited: 1
Mahesh Swaminathan, Akhil Jain, Sungchul Daniel Choi, et al.
Expert Review of Hematology (2024)
Closed Access | Times Cited: 1
Advances in pharmacotherapy for myelofibrosis: what is the current state of play?
Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 743-754
Closed Access
Mario Tiribelli, Gianluca Morelli, Massimiliano Bonifacio
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 6, pp. 743-754
Closed Access
